Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
Subscribe To Our Newsletter & Stay Updated
